Neurogene (NGNE) Competitors

Pharvaris (NASDAQ:PHVS) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Do insiders and institutionals believe in PHVS or NGNE?

52.4% of Neurogene shares are held by institutional investors. 9.9% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media prefer PHVS or NGNE?

In the previous week, Pharvaris had 9 more articles in the media than Neurogene. MarketBeat recorded 10 mentions for Pharvaris and 1 mentions for Neurogene. Neurogene's average media sentiment score of 1.02 beat Pharvaris' score of 1.00 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, PHVS or NGNE?

Pharvaris has a beta of -2.81, suggesting that its stock price is 381% less volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Do analysts prefer PHVS or NGNE?

Pharvaris currently has a consensus target price of $35.60, indicating a potential upside of 50.53%. Neurogene has a consensus target price of $46.17, indicating a potential upside of 131.06%. Given Neurogene's higher possible upside, analysts plainly believe Neurogene is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Neurogene	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has better valuation and earnings, PHVS or NGNE?

Neurogene has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$145.24M	-$3.36	-7.04
Neurogene	$930K	306.57	-$75.14M	-$4.31	-4.64

Is PHVS or NGNE more profitable?

Neurogene's return on equity of -33.33% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-69.09%	-63.34%
Neurogene	N/A	-33.33%	-30.34%

Summary

Neurogene beats Pharvaris on 10 of the 13 factors compared between the two stocks.